Welcome to our dedicated page for Resmed SEC filings (Ticker: RMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The ResMed Inc. (RMD) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. ResMed’s common stock is registered under Section 12(b) of the Exchange Act and trades on the New York Stock Exchange under the symbol RMD, and its filings offer detailed insight into governance, compensation, capital returns, and financial performance.
Among the key documents available are Form 8-K current reports, where ResMed discloses material events. Recent 8-K filings describe quarterly and annual results of operations, dividend declarations, and changes in the composition of the board of directors. They also cover amendments to equity-based incentive plans and the employee stock purchase plan, including increases in reserved shares and changes to plan terms approved by stockholders at the annual meeting.
Investors can also review the company’s Definitive Proxy Statement on Schedule 14A, which discusses board structure, director elections, executive compensation, and long-term strategic priorities. The proxy materials outline ResMed’s mission around sleep and breathing health, its 2030 goals, and its approach to aligning incentive programs with performance and shareholder interests.
On Stock Titan, these filings are complemented by AI-powered summaries that help explain complex sections, such as compensation plans, dividend announcements, and voting results from the annual meeting. Users can quickly see what the board has approved, how stockholders voted on proposals, and how ResMed’s capital management policies, including recurring cash dividends, are documented in its official records.
Because Form 8-K reports and proxy statements are updated over time, the filings page offers a chronological view of ResMed’s regulatory history, from financial disclosures to governance changes. This makes it a useful resource for investors who want to understand how the company reports its performance, manages equity plans, and communicates significant events through the SEC’s EDGAR system.
ResMed Inc. director reports planned stock sale. A reporting person serving as a director of ResMed Inc. (ticker RMD) sold 2,000 shares of ResMed common stock on 12/03/2025 at a price of $251.47 per share. The transaction was coded as a sale and was made under a Rule 10b5-1 trading plan adopted on August 12, 2025, which allows pre-arranged trades according to preset instructions. Following this sale, the insider directly beneficially owns 68,773 shares of ResMed common stock, reflecting the remaining stake reported in this filing.
Peter C Farrell has filed a notice to sell up to 2,000 shares of common stock under Rule 144. The planned sale has an aggregate market value of $502,860, to be executed through Merrill Lynch on or around 12/03/2025 on the NYSE. The filing notes that 44,448,959 shares of this class are outstanding.
The 2,000 shares being sold were acquired through stock option exercises on three dates between 2014 and 2015, all paid in cash. The notice also reports that the same seller disposed of 2,000 common shares in the past three months, on 11/12/2025, generating gross proceeds of $504,020.
ResMed Inc. reported an insider stock sale by its Global General Counsel. The Form 4 shows that officer Michael J. Rider sold 50 shares of ResMed common stock on 12/01/2025 at a price of $244.16 per share. After this transaction, he beneficially owned 9,791 shares of ResMed common stock directly.
The filing notes that the sale was made under a pre-arranged Rule 10b5-1 trading plan that was adopted on February 28, 2025, which is designed to allow insiders to sell shares according to a set schedule.
ResMed Inc.'s Chief Financial Officer reports a routine stock sale. On 12/01/2025, the CFO sold 1,000 shares of ResMed common stock at a price of $244.16 per share in an open market transaction. The filing notes that this sale was conducted under a pre-arranged Rule 10b5-1 trading plan that was adopted on February 19, 2025, which is designed to allow insider transactions under preset instructions.
After this transaction, the CFO continues to beneficially own 87,495 ResMed shares, held directly. The filing does not report any derivative securities transactions, indicating that this update relates only to common stock ownership.
An insider of RMD has filed a notice to sell 1,000 shares of common stock through Fidelity Brokerage Services on the NYSE, with an aggregate market value of $244,160. These shares were acquired on 11/11/2022 through restricted stock vesting as compensation from the issuer.
In the past three months, the same seller reported three additional sales: 3,000 shares on 09/02/2025 for gross proceeds of $812,310, 3,000 shares on 10/01/2025 for $823,080, and 3,000 shares on 11/03/2025 for $742,620. The issuer lists 145,966,294 shares of common stock outstanding, providing scale versus these planned and recent insider sales.
ResMed Inc. (RMD) reported an equity compensation grant to its Chairman and CEO on a Form 4. On 11/24/2025, he received options to purchase 33,288 shares of ResMed common stock at an exercise price of $250.52 per share. These options first become exercisable on 11/11/2026 and vest in three equal annual installments starting on that date, aligning his incentives with longer-term company performance. Following this grant, he beneficially owns 466,223 shares of ResMed common stock held directly.
ResMed Inc. (RMD)1,331 stock options on ResMed common stock with an exercise price of $250.52 per share. These options become exercisable on the earlier of November 11, 2026, or the date of the first annual meeting of stockholders following the grant date, and expire on November 11, 2032.
After this reported transaction, the director beneficially owns 70,773 shares of ResMed common stock directly, as well as 1,331 stock options directly.
ResMed Inc. (RMD) director files Form 4 for planned stock sale. Director Jan De Witte reported selling 2,055 shares of ResMed common stock on 11/25/2025 at a price of $255 per share. After this transaction, De Witte beneficially owns 4,261 shares, held directly.
The sale was coded as an "S" transaction and was carried out under a Rule 10b5-1 trading plan adopted on August 18, 2025, indicating it was pre-arranged under preset instructions rather than a discretionary, one-off trade.
ResMed Inc. director Nicole Mowad-Nassar reported equity transactions involving the company’s stock. As a member of the board of directors, she filed a Form 4 as a single reporting person.
On 11/24/2025, she was granted stock options on 1,331 shares of ResMed common stock at an exercise price of
ResMed Inc. insider plans sale of common shares under Rule 144. The notice covers a proposed sale of 2,055 common shares through Fidelity Brokerage Services LLC on the NYSE, with an aggregate market value of $524,025.00. The issuer has 145,966,294 common shares outstanding. The shares derive from restricted stock vesting awards granted as compensation on 11/11/2021 and 11/11/2024.
During the past three months, the same seller, Jan De Witte, sold 487 common shares on 11/11/2025 for gross proceeds of $121,871.75. By signing the notice, the seller represents that he does not know any material adverse information about ResMed’s current or prospective operations that has not been publicly disclosed.